Tsuyoshi Fukuda, PhD
is director of the pharmacogenetics laboratory in the Division of Clinical Pharmacology. He focuses on drug metabolizing enzyme and transporter genetic variants, PK and response to medication and adverse drug events. He has developed innovative approaches in pharmacogenetic assay development, data analyses, integrated PK/PD/PG modeling of the clinical data set, and physiologically based pharmacokinetic (PBPK) analysis and model development.
513-803-0428
tsuyoshi.fukuda@cchmc.org
Tsuyoshi Fukuda, PhD
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Clinical pharmacology (pharmacogenetics, pharmacokinetics and pharmacodynamics)
Biography
Dr. Fukuda received his Pharmacy degree and PhD in Pharmaceutical Science from Osaka University, Japan. He received postdoctoral training in the department of Clinical Pharmacology and Pharmacogenomics (Prof. J. Azuma, MD) and served as an Assistant Professor at Osaka University, Graduate School of Pharmaceutical Sciences. Dr. Fukuda spent over 10 years in the field of Clinical Pharmacology while engaged in Pharmacogenetic research. Dr. Fukuda’s efforts have resulted in over 40 peer-reviewed publications with project members that include Master level and Ph.D. students, clinical fellows, and private sector R & D staff. He was awarded The Japanese Society of Clinical Pharmacology and Therapeutics Research Prize as its youngest recipient in 2003. Dr. Fukuda joined the Division of Clinical Pharmacology (Prof. Alexander A Vinks, PharmD, PhD) at Cincinnati Children's Hospital Medical Center in 2007. His current research interests include the clinical application of pharmacogenetics and pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation, focusing on improving our understanding of inter-patient differences in drug response and developing individualized dosing strategies in pediatric patients.
Education and Training
BS: Osaka University, School of Pharmacy, Osaka, Japan, 1995.
Pharmacist: Japan, 1995.
MS: Osaka University, Osaka, Japan,1997.
PhD: Osaka University, Osaka, Japan, 2000.
Certification: Clinical Pharmacology (Pharmacist), 2003 (Japanese Society of Clinical Pharmacology), 2008 renewed.
Publications
View PubMed Publications
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24. doi: 10.2165/11536640-000000000-00000.PMID: 21142265
Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-Onset Systemic Lupus Erythematosus. Semin Arthritis Rheum. 2010 Jul 22.
Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23.
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet 2010.
Nakamura N, Fukuda T, Nonen S, Hashimoto K, Azuma J, Gemma N. Simple and accurate determination of CYP2D6 gene copy number by a loop-mediated isothermal amplification method and an electrochemical DNA chip. Clinical Chem Act 2010 Jan 20.
Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495-500.
Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):115-23. Yamamoto A, Nonen S, Fukuda T, Yamazaki H, Azuma J. Genetic polymorphisms of glycine N-acyltransferase in Japanese individuals. Drug Metab Pharmacokinet. 2009;24(1):114-7. Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Serretti A, Azuma J, Kinoshita T. 5-HT1A gene polymorphisms contributed to antidepressant response in major depression. Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Feb;29(1):23-31. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008 15;32(2):398-404.
Grants
|
Alexander A. Vinks, PharmD, PhD, FCP
Director, Division of Clinical Pharmacology
is interested in population and physiologically based PK/PD modeling, pharmacogenetics (PG) and the application of genomic, population and simulation approaches (pharmacometrics) to pediatric clinical trial design and the development of Bayesian dosing algorithms. He is program director of the Cincinnati Training Program in Pediatric Clinical and Developmental Pharmacology and a founder and co-director of the Genetic Pharmacology Service.
513-636-0159
sander.vinks@cchmc.org
Alexander A. Vinks, PharmD, PhD, FCP
Director, Division of Clinical Pharmacology
Academic Information
Professor, UC Department of Pediatrics
Professor, Adjunct Professor of Pharmacology
Show All
Biography
Dr. Vinks received his MS in Pharmacology from the University of Toronto, Canada and a Pharmacy degree and PhD in Pharmacology from Leiden University, The Netherlands. He was trained as a hospital pharmacist (PharmD) and clinical pharmacologist at The Hague Hospitals Central Pharmacy, The Hague, The Netherlands. Before joining the Division of Pharmacology Research at Cincinnati Children's Hospital Medical Center, he was Director of the Clinical Pharmacology & Toxicology Laboratory at The Hague. Dr. Vinks has spent over 20 years in the field of Therapeutic Drug Monitoring and applied pharmacokinetics, both in the research aspects of population pharmacokinetic studies, as well as in the clinical application of these approaches to clinical patient care. Dr. Vinks holds an academic appointment with the University of Cincinnati Collegeof Medicine and is the Principal Investigator for the Pediatric Pharmacology Research Unit (PPRU). He is director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management (LAP/TDM) and clinical pharmacology fellowship program at Cincinnati Children's. His current research interests include pharmacokinetic-pharmacodynamic (PK-PD) modeling and the application of population and simulation methods in TDM and clinical trial design. He has authored over 50 publications in the area of TDM, pharmacokinetics and clinical pharmacology. Dr. Vinks has been actively involved with International Association of Therapeutic Drug Monitoring and Clinical Toxicology from the beginning. He is chair of the TDM cost-effectiveness committee, serves as Secretary of the Executive Board of Directors, and is on the Editorial Board of the journal Therapeutic Drug Monitoring. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.
Education and Training
Certification American Board of Clinical Pharmacology, 2001. PhD Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996. PharmD Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986 . MS Pharmacology, University of Toronto, Toronto Canada, 1983. MS Pharmacy, Leiden University, Leiden, The Netherlands, 1982.
Publications
View PubMed Publications
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24.
Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and pharmacodynamics of mycophenolic Acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2011 Feb;40(4):307-13.
Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.
Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23.
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9. Vargus-Adams JN, McMahon MA, Michaud LJ, Bean J, Vinks AA. Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. PM R. 2010 Jan;2(1):37-42.
Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.
Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.
Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495-500.
Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008 May-Jun;22(3):281-91.
Grants
|
